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Background: The REDUCE-RISK trial was set up to compare the effectiveness of weekly subcutaneously administered
methotrexate with daily oral azathioprine or 6-mercaptopurine in low-risk Crohn disease (CD) or subcutaneously administered
adalimumab (ADA) in high-risk CD in a pediatric population (age 6-17 years).
Objective: The aim of this study is to perform a systematic review to provide input into the research protocol to gather the
necessary information to improve the performance of an evidence-based economic evaluation when the trial is finished.
Methods: The Centre for Reviews and Dissemination (CRD) Health Technology Assessment (HTA) database, websites of HTA
institutes, CRD’s National Health Service Economic Evaluation Database, MEDLINE (OVID), and Embase databases were
consulted to retrieve (reviews of) relevant economic evaluations. Studies were eligible if they included a pediatric or adult
population with inflammatory bowel diseases (CD and ulcerative colitis [UC]) treated with ADA (Humira). There were no
restrictions on the comparator. Only economic evaluations expressing outcomes in life years gained or quality-adjusted life years
gained were selected.
Results: A total of 12 primary studies were identified. None of these studies included a pediatric population because of a lack
of supporting trials. The economic evaluations identified in our systematic review indicate that ADA is an appropriate intervention
for inclusion in such a trial. From a health economic point of view, it is important to make an incremental analysis comparing
such an intervention with standard care and not immediately versus another (expensive) biological treatment. Information on the
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impact of children’s school attendance and parents’ productivity is currently lacking in economic evaluations, and none of the
underlying trials measured quality of life (QoL) using a generic utility instrument.
Conclusions: The review of the economic literature on ADA for the treatment of patients with CD supports the performance
of a trial with biologicals in pediatric patients, including making a distinction according to disease severity. Conducting an
economic literature review enabled us to decide which variables should be added to the research protocol from an economic point
of view. Measurements for children’s and parents’ QoL (EuroQol 5-Dimension questionnaires), children’s school attendance,
and parents’ productivity (WPAI-CD-CG questionnaire) were added to the research protocol. This will provide support for the
calculation of the cost-effectiveness of the interventions evaluated in the REDUCE-RISK trial.
Trial Registration: ClinicalTrials.gov NCT02852694; https://clinicaltrials.gov/ct2/show/NCT02852694
(JMIR Form Res 2021;5(1):e13888) doi: 10.2196/13888
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Introduction
The REDUCE-RISK Trial
Immunomodulators such as thiopurines (azathioprine [AZA]
or 6-mercaptopurine [6-MP]), methotrexate (MTX), and
biologicals such as adalimumab (ADA) are well established for
the maintenance of remission in pediatric Crohn disease (CD).
However, it remains unclear which maintenance medication
should be used first line in specific patient groups. The
REDUCE-RISK trial (Risk-stratified randomized controlled
trial in paediatric Crohn’s Disease: Methotrexate versus
azathioprine or adalimumab for maintaining remission in
patients at low or at high risk for aggressive disease course,
respectively – a treatment strategy) aims to compare the efficacy
of maintenance therapies in newly diagnosed CD based on
stratification into high- and low-risk groups for severe CD
evolution: (1) MTX versus AZA/6-MP in low-risk patients and
(2) MTX versus ADA in high-risk patients. Patients are eligible
if aged 6 to 17 years with new-onset (<6 months)
treatment-naïve active and/or perianal fistulizing CD and
receiving steroids or exclusive enteral nutrition (EEN) for
induction of remission. They are stratified into low- and
high-risk groups based on phenotype and disease response to
induction therapy. Individual informed consent is obtained
before participation in the study. Patients are followed up for
12 months post randomization at prespecified intervals. The
primary endpoint is sustained steroid or EEN-free remission at
12 months [1].
The REDUCE-RISK trial, an international multicenter
open-label prospective randomized controlled trial (RCT), has
received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement
number 668023. This trial has been reviewed and approved by
the National Ethics Services of participating countries and is
prospectively registered (ClinicalTrials.gov Identifier:
NCT02852694; date of registration: June 9, 2016; EudraCT
Number: 2016-000522-18).
Background on Health Technology Assessment and
Economic Evaluations
When setting up the protocol for REDUCE-RISK, the research
team prepared to allow the performance of a full health
technology assessment (HTA). The European Network for HTA
(EUnetHTA) describes HTA as “a multidisciplinary process
that summarizes information about the medical, social, economic
and ethical issues related to the use of a health technology in a
systematic, transparent, unbiased, robust manner. Its aim is to
inform the formulation of safe, effective, health policies that
are patient focused and seek to achieve best value. Despite its
policy goals, HTA must always be firmly rooted in research
and the scientific method.” In HTA, an economic evaluation is
performed to determine whether an intervention offers value
for money in comparison with other alternatives. This economic
consideration might provide support to policy makers when
making decisions while trying to make efficient use of limited
resources.
An economic evaluation is “the comparative analysis of
alternative courses of action in terms of both their costs and
consequences” [2]. In an economic evaluation, the incremental
cost-effectiveness ratio (ICER) is calculated using the following
general formula:
ICER=IC/IE=(CInt−CComp)/(EInt−EComp)
with C being the costs, Comp the comparator, E the effects, IC
the incremental cost, IE the incremental effect, and Int the
intervention.
This formula shows that the focus should be on the incremental
elements, that is, those that differ between the compared
alternatives. Economic evaluations can be performed from
different perspectives. As mentioned in the EUnetHTA guideline
on methods for health economic evaluations [3], “economic
evaluations should at minimum be conducted from a health care
perspective. However, several countries require a societal
perspective.” To make the results of the international
REDUCE-RISK trial useful for researchers and policy makers
in different countries, incremental elements for both the health
care payer and societal perspective will be taken into account.
A Review of the Literature to Provide Input to the
Research Protocol
In preparation of a future economic evaluation, we determine
the most important incremental elements. The International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) guidelines state that “assessing relative value is rarely
the primary purpose of an experimental study. Nevertheless,
when the decision is made to conduct an economic evaluation
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alongside a clinical trial, it is important that the economic
investigator contributes to the design of the study to ensure that
the trial will provide the data necessary for a high-quality
economic evaluation” [4]. Our research question is which
additional elements should we include in the research protocol
of the REDUCE-RISK trial to provide support to a high-quality
economic evaluation? Therefore, a systematic search for
economic literature about the cost-effectiveness of ADA
(Humira) for the treatment of inflammatory bowel disease (IBD)
was performed.
The purpose of this systematic review is to obtain more useful
insights and knowledge from previous economic studies [5].
These previous economic evaluations guide us in finding the
key variables that enable us to provide well-directed input for
the research protocol. In this paper, the review of the economic
literature is transparently presented. No official review protocol
was established for the systematic review. The findings are used
to provide input for the research protocol from a health
economic point of view (eg, to decide which questionnaires
should be added to the research protocol). On the other hand,
we also want to avoid overloading the research protocol and
only focus on the incremental elements that influence an
intervention’s cost-effectiveness. The results of this systematic
review help us to focus on gathering the right information in
the REDUCE-RISK trial, which will support researchers at the
end of the trial to make a high-quality economic evaluation.
Methods
A systematic review of the literature was conducted using
predefined selection criteria that included considerations of
population, intervention, comparator, and design. As the goal
of this study is to provide input for the research protocol, the
applied selection criteria were not too restrictive. Studies were
included if (1) the population included children or adults with
IBD (CD and ulcerative colitis [UC]); (2) ADA was one of the
included interventions; and (3) the design reflected a full
economic evaluation, that is, studies comparing at least two
alternative treatments in terms of costs and outcomes and
expressing outcomes in life years gained or quality-adjusted
life years (QALYs) gained. No restrictions were applied to the
comparator. Studies were excluded if they only considered other
treatments than ADA at the moment of randomization. Studies
that only included switching to ADA in case of no response to
the interventions under consideration (ie, not including ADA
at the moment of randomization) were not selected. Cost
analysis or cost-of-illness studies did not fulfill the
aforementioned definition of an economic evaluation and were
excluded. As summarized in an EUnetHTA guideline providing
an overview of national guidelines for 25 countries, “all
countries except four specify that the preferred outcome measure
is QALYs or both QALYs and life years. Of the four countries
with guidelines that do not announce QALYs as a preferred
method, at least three accept QALYs in special circumstances
or in complementary analyses” [3]. In this study, we focus on
these preferred outcomes. Studies expressing results in
disease-specific outcomes (eg, cost per remission [6,7], cost per
responder [8], or cost per mucosal healing [9]) are thus excluded.
Before-after analyses [10] comparing the costs before and after
the start of treatment with ADA were also excluded, as they
also do not fulfill the definition of an economic evaluation (ie,
lack of a comparative intervention). Abstracts were excluded
because of a lack of sufficient details to allow for a proper
evaluation. No time restriction was imposed. English, French,
German, and Dutch papers were eligible.
Various databases were consulted. In February 2016, before the
final protocol was set up, reviews on this topic were searched
by consulting the Centre for Reviews and Dissemination (CRD)
HTA database and HTA institute websites listed on the
International Network of Agencies for Health Technology
Assessment website. The websites of ex- or nonmember HTA
institutes such as the National Institute for Health and Care
Excellence (NICE) were also consulted. In September 2016,
CRD’s National Health Service Economic Evaluation Database,
MEDLINE (OVID), and Embase databases were searched to
retrieve both full economic evaluations and reviews of full
economic evaluations of ADA for IBD treatment. To ensure
reproducibility, further details of the search strategy are provided
in Multimedia Appendix 1.
The selection of relevant papers was performed in a 2-step
procedure: an initial assessment of the title, abstract, and
keywords, followed by a full-text assessment of the selected
references. When no abstract was available and the citation was
unclear or ambiguous, consideration of the citation was made
directly on the basis of a full-text assessment. Reference lists
of the selected studies were checked for additional relevant
citations. The procedure was performed by a health economist
(MN), and in case of doubt for medical reasons, a medical
specialist (GV) provided support.
The primary full economic evaluations were summarized in an
in-house data extraction sheet listing all variables (eg,
population, intervention, comparators, and quality of life [QoL]
input) and summary measures (eg, ICERs and results of
sensitivity analyses) for which data were sought (Multimedia
Appendix 1). The information gathered in these sheets reflects
the elements that are usually reported in an economic evaluation
(eg, according to the Consolidated Health Economic Evaluation
Reporting Standards [CHEERS] guidelines [11,12]). This
information was used to set up summary tables that form the
basis for a further critical assessment. On the basis of the results
of this assessment, we judged whether from an HTA and
economic perspective, elements in the research protocol of the
REDUCE-RISK trial could be added.
Results
Article Selection
Figure 1 presents the flowchart of the selection process. A total
of 12 papers were identified in the electronic databases. Four
additional references were identified by searching websites of
HTA institutes. Information from 3 journal papers [13-15] and
1 report [16] were already published in an HTA report. To avoid
overlap, only the 12 primary studies [17-28] will be further
discussed. The list of the 16 identified economic evaluations
and information on duplicates is provided in Multimedia
Appendix 2.
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Figure 1. Selection of relevant articles.
General Information
Half of the studies were performed for the United Kingdom
(n=6; Table 1). Two studies conducted an analysis for Canada,
another 3 for the United States, and 1 for Poland. All but one
of the studies explicitly declared the presence or absence of
conflicts of interest. All studies were cost-utility analyses. Most
short-term models (1 year) applied a decision tree, whereas
long-term analyses (5, 10, or 30 years or lifetime) are Markov
models or a combination of an initial decision tree and a Markov
component. For the long-term models, applied discount rates
are in agreement with national recommendations in all but one
of the analyses. In this study, the manufacturer assumed an
annual discount rate of 3% for both health and cost outcomes,
although the Canadian Agency for Drugs and Technologies in
Health (CADTH) guidelines recommend a 5% discount rate
[19]. However, a 5% discount was applied in the sensitivity
analysis. For further details, we refer to section 2.3.1 of the
Multimedia Appendix 1.
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55 yearsMarkovCUANoCanadaAssasi et al [18]
3.5Lifetime (60 years)MarkovCUANoUnited KingdomBodger et al [23]
310 yearsMarkovCUAYes or nogCanadaCADTH [19]
—h1 yearMarkovCUANoUnited KingdomDretzke et al [20]
—1 year (56 weeks)MarkovCUAYesN/AAbbott submissioni
3.510 yearsDecision
tree+Markov
CUAYes or nojUnited KingdomEssat et al [21]
—1 yearDecision treeCUAYesUnited StatesKaplan et al [24]
3.51 yearRegression modelCUAYesUnited KingdomLoftus et al [25]
3.510 yearsDecision
tree+Markov
CUAYes or nojUnited KingdomRafia et al [22]
Costs: 5; Ef-
fects: 3.5
30 yearsMarkovCUANoPolandStawowczyk et al [26]
—1 year (54 weeks)Decision treeCUANot declaredUnited StatesTang et al [27]
—1 year (56 weeks)Decision treeCUAYesUnited StatesYu et al [28]
aCoI: conflict of interest.
bDiscount rate for both costs and effects, unless otherwise mentioned.
cCUA: cost-utility analysis.
dThe AbbVie and MSD submissions are part of the report published by Archer et al [17].
eN/A: not applicable. This submission is part of the UK report in which it was published.
fMSD: Merck Sharp & Dohme.
gSubmission by the manufacturer reviewed by the CADTH team (Common Drug Review Analyses).
hNo discount rate is applied because of the short time horizon of 1 year.
iAbbott submission is part of the report published by Dretzke et al [20].
jThe manufacturer submitted a model-based health economic analysis as part of their submission, which was then evaluated by a team of researchers
from the School of Health and Related Research.
Population and Compared Interventions
None of the studies included a pediatric population. The primary
economic evaluations investigated treatment strategies for adult
patients (average age 35-40 years and average weight 69-77 kg)
with moderate-to-severe UC or CD. In two studies, a secondary
analysis is considered for the pediatric population [17,20]. The
authors consider this as an exploratory analysis, as the efficacy
data are drawn from trials undertaken within an adult UC
population [17].
Most studies explicitly mention that patients failed (intolerance,
inadequate response, or loss of response) to respond to standard
therapy before ADA was considered. In all but 3 studies
[24,27,28] and the MSD submission [17], conventional
nonbiological therapy is considered as a comparator. This
usually exists as a mix of 5-aminosalicylates (5-ASAs),
corticosteroids, and immunosuppressants. In 2 studies, only
biologicals are included [24,28]. The study by Kaplan et al [24]
considered whether dose escalation of infliximab (IFX; to 10
mg/kg every 8 weeks) is a cost-effective strategy compared with
ADA initiation after loss of response to 5 mg/kg of IFX. In
addition, Yu et al [28] compared IFX and ADA. This study was
also part of the Abbott submission, which contained 2 models:
one comparing the cost-effectiveness of ADA as a maintenance
therapy against standard care (SC) and the other comparing the
cost-effectiveness of ADA and IFX as maintenance therapies
[20]. The report of Dretzke et al [20], which made a critical
assessment of Abbott’s submission, concentrates on the model
including SC as a treatment option (refer to the Discussion
section).
In 2 studies [17,21] and the MSD submission [17], surgery
(colectomy) is considered as an initial treatment option. In these
studies, surgery is included as an alternative treatment strategy
and a downstream component of the pathway for patients in the
other treatment strategies. In other models, such as the models
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discussed in the CADTH report [19] and from the AbbVie
submission [17], surgery is not considered a direct comparator
but only included as a treatment for patients who failed both
biological and nonbiological drug treatments.
Next to ADA, the most frequently included biological treatments
are IFX, golimumab, and vedolizumab. Certolizumab pegol and
natalizumab are also included in individual studies. In most
studies, ADA was administered as follows: induction—160 mg
(week 0), 80 mg (week 2); maintenance—40 mg every other
week (starting from week 4) [17-19,21,24,26-28]. In other
studies, the following treatment schedule was applied:
induction—80 mg (week 0), 40 mg (week 2); maintenance—40
mg every other week [20,22,23,25]. The duration of treatment
might also be different but is not always clearly stated. Bodger
et al [23] included 1 or 2 years of treatment with ADA or IFX,
after which patients return to SC. For further information on
the treatment schedule of the other interventions and dose
escalation, we refer to section 2.3.2 of Multimedia Appendix
1.
Costs
Most economic evaluations are performed from the perspective
of the health care payer. Tang et al [27] took the perspective of
a managed care organization in the United States and excluded
patient co-payments. Only 2 studies applied a broader societal
perspective, including costs related to lost productivity. Loftus
et al [25] assumed that each CD-related hospitalization
corresponds to a missed interval of work equal to the average
duration of serious adverse events (AEs) leading to
hospitalization (on average 16.55 days based on the Crohn’s
Trial of the Fully Human Antibody Adalimumab for Remission
Maintenance (CHARM) trial [29]). This was then multiplied
by an 8-hour workday and an average hourly wage in the United
Kingdom of £13.00 (US $17.6) [25]. Stawowczyk et al [26]
included indirect costs based on an unpublished study carried
out in Poland on 202 patients with UC. Indirect costs included
absenteeism, presenteeism, and leaving the labor market earlier.
Yearly indirect costs for remitted patients counted as PLN 6524
(US $1767) [26]. For patients with active disease, this was PLN
22,935 (US $6211). An overview of the perspective, currency,
and year of costing is provided in Multimedia Appendix 1.
Costs of Biological Treatments
An overview of the unit costs of biological treatments is
provided in Multimedia Appendix 1. It is remarkable that
although the unit cost for 40 mg of ADA is lower than 100 mg
of IFX in the studies for the United Kingdom [17,21,22] and
Canada [18,19], this is the opposite in all US studies [24,27,28].
However, IFX is assumed to be administered in a day-case
setting, whereas ADA can be self-administered subcutaneously.
As a result, the total treatment costs with IFX are not always
lower if administration costs are also taken into account. For
example, in the study of Yu et al [28], the total therapy cost for
ADA equals the drug costs of US $17,176. For IFX, the total
therapy cost of US $18,214 consists of the drug costs (US
$14,663), the drug administration costs (US $1605), and excess
uninfused drug costs (US $1946). Differences in start-up dose
or dose escalation probabilities further influence total treatment
costs (Multimedia Appendix 1).
Costs of Standard Care
The costs of SC are substantially lower than those of biological
treatment costs. In the study by Archer et al [17], SC in the
induction phase of 8 weeks, consisting of 5-ASAs, AZA, 6-MP,
and prednisolone, costs £167.6 (US $227.4). In the maintenance
phase of 26 weeks, this is £343.8 (US $466.4). The same use
of background therapies is assumed for all biological treatment
arms. Standard care cost differences were small between the
different treatment strategies. For example, in their model
comparing golimumab with ADA, IFX, or SC, the background
therapy costs were £251.43 (US $341.1) per cycle for the
standard nonbiological treatment group versus £200.03 (US
$271.4) per cycle for the biological treatments during the
induction treatment (cycle=8 weeks). During maintenance
treatment (cycle=2 months), this was £121.15 (US $164.4)
versus £120.98 (US $164.1), respectively [17]. Assasi et al [18]
include a total non-anti-TNF outpatient drug costs per cycle (8
weeks) of CAD 116.30 (US $91.6) for drug responsive patients
and CAD 85.95 (US $67.7) for drug refractory patients. In the
report of Essat et al [21], conventional treatment (balsalazide,
mesalazine, olsalazine, sulfasalazine, budesonide, prednisolone,
AZA, 6-MP, and MTX) costs £153.6 (US $208.3) per induction
cycle (6 weeks) and £204.8 per maintenance cycle (8 weeks).
The authors assume that while patients are receiving biological
therapy, the costs of conventional therapies are halved (£102.4
[US $138.9]). The same logic is applied in the study of Rafia
et al [22], with a cost of £52.62 (US $71.4) per induction cycle
and £70.16 (US $95.2) per maintenance cycle, which is halved
(£35.08 [US $47.6]) for patients while receiving biological
treatment. In the Polish study, standard treatment costs per cycle
(8 weeks) are PLN 204 (US $55.3) [26]. Thus, the incremental
impact of these costs is minimal in comparison with the
biological treatment costs.
Costs of Colectomy or Surgery
From the 3 studies including colectomy as an alternative
treatment strategy, Archer and Essat refer to information from
the study of Buchanan et al [30] to include a cost of £13,452
(US $18,242) [17] and £13,577 (US $18,412) [21] for surgery.
In the MSD submission [17], the cost for colectomy is £8968
(US $12,160). Other studies include surgery as an event in their
model, without providing further details on the type of
hospitalization. A wide range of costs is mentioned: the surgery
cost is PLN 12,480 (US $3380) in the Polish study of
Stawowczyk et al [26] up to $31,923 for a hospital unit cost in
the US study of Yu et al [28]. The cost of surgery was $11,341
in the US study of Kaplan et al [24], £10,581 (US $14,351) in
the UK study of Rafia et al [22], and CAD 19,269 (US $15,171)
in the CADTH study [19].
Incremental Costs Related to AEs
Archer et al [17] report that serious and severe AEs were not
considered in the AbbVie model. The manufacturer notes that
most AEs experienced by patients were nonserious and
considered to be unrelated to the study drugs (based on results
from the ULTRA2 trial [31]) [17]. In addition, the manufacturer
highlights that the exclusion of these events represents a
conservative assumption as “the ULTRA2 trial reported slightly
higher incidences of serious and severe AEs in the placebo arm
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than in the adalimumab arm of the trial; therefore, considering
serious and severe AEs in the model would have increased
medical costs and reduced health gains within the conventional
management group” [17]. In addition, the Polish study refers
to the ULTRA2 trial [31] to justify that certain AEs were not
included in the model because ADA treatment was generally
well tolerated and the overall safety profile of ADA was
comparable with that of placebo [26]. Rafia et al [22] also
indicate that the impact of AEs on the ICER is minimal. Finally,
Tang et al [27] mention that they are not aware of evidence that
demonstrates large differences in the proportion of adverse drug
reactions across the 4 biological treatments (ADA, IFX,
certolizumab pegol, and natalizumab), and the frequency of
these complications is low. On the basis of their clinical
judgment, they conclude that adverse drug reactions should not
be included in the structure of the model. Progressive multifocal
leukoencephalopathy occurrence with natalizumab was
considered a rare but significant AE with a treatment cost
between $14,544 (lower limit) and $22,725 (upper limit) [27].
QoL
Archer et al [17] performed a systematic literature search for
utility values. A total of 10 studies reported EuroQol
5-Dimension (EQ-5D) estimates for one or more health states
relevant to their model (Multimedia Appendix 1). The authors
considered the values reported by Woehl et al [32] and Swinburn
et al [33] to be the most useful as “they are UK based, included
a fairly large number of patients (n=180 and n=230,
respectively) and have the greatest coverage of the health states
in the model” [17]. Unfortunately, both studies are only
published as an abstract. Swinburn et al [33] included 230 UC
patients (postsurgery [n=30], remission [n=78], mild disease
[n=47], moderate disease [n=31], and severe disease [n=44]).
The EQ-5D utility scores were collected via an online survey.
The results are presented in a figure in the abstract, without
mentioning the exact utility values. Archer et al [17] extracted
utility values from this graph: for patients who had not
undergone surgery, the utility scores for each disease severity
were as follows: remission 0.91 (95% CI 0.87-0.95), mild
disease 0.80 (95% CI 0.70-0.85), moderate disease 0.68 (95%
CI 0.58-0.78), and severe disease 0.45 (95% CI 0.35-0.55).
Archer et al [17] extracted the following mean EQ-5D scores
from the study of Woehl et al [32]: remission 0.87 (SD 0.15),
mild disease 0.76 (SD 0.18), and moderate-to-severe disease
0.41 (SD 0.34).
None of the identified economic evaluations is based on an
RCT, including a head-to-head comparison of the relevant
intervention and comparator, in which utilities are measured
with a generic utility instrument. Next to the previously
mentioned studies of Woehl et al [32] and Swinburn et al [33],
a variety of other sources and assumptions were used in the
other identified economic evaluations. We refer to section 2.3.5
of Multimedia Appendix 1 for further details. Most economic
evaluations refer to the study of Gregor et al [34] to retrieve
relevant utility values. They used the time trade-off (TTO),
Standard Gamble (SG), and Visual Analog Scale (VAS) methods
in 180 consecutive patients with CD to obtain utilities. All but
one of the studies referring to Gregor et al [34] mentioned the
use of values from the SG approach [18,24,25,27,28]. Only
Dretzke et al [20] used the TTO values. The results for the SG
technique were as follows: mild disease, 0.82; moderate disease,
0.73; and severe disease, 0.54 [34]. For the TTO technique,
these were 0.96, 0.88, and 0.71, respectively. A second table
presented the following mean utility scores for the SG technique
at the initial visits: chronically active therapy resistant, 0.74;
chronically active therapy responsive, 0.86; acute disease
exacerbation, 0.77; remission, 0.88; and overall, 0.81. With the
TTO approach, these were 0.88, 0.98, 0.89, 0.96, and 0.92,
respectively [34].
Bodger et al [23] mapped the midpoint CD Activity Index
(CDAI) scores to EQ-5D utility scores. An algorithm developed
by Buxton et al [35] was used (EQ-5D=0.9168−0.0012×CDAI).
This algorithm was based on multiple observations from 905
patients with moderate-to-severe CD who participated in the
Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1)
and Evaluation of Natalizumab as Continuous Therapy
(ENACT-2) clinical trials [36]. We refer to our discussion on
QoL for some critical remarks from the authors who developed
this algorithm.
Finally, large differences are observed in the postsurgery
remission utility values. Several studies assign a value equal
[18] or similar [24,27] to the utility for (medical) remission. In
contrast, several other studies assign a much lower value for
postsurgery remission. For example, in the MSD submission,
the utility value for postcolectomy remission (0.60) was assumed
to be equal to the utility value for late complications
(postcolectomy). Similar values for postsurgery remission were
assumed in the study discussed in the CADTH report (0.67)
[19] and in the studies by Essat et al (0.60) [21], Rafia et al
(0.57) [22], and Stawowczyk et al (0.61) [26], whereas remission
utility values were much higher—0.82, 0.86, 0.82, and 0.88,
respectively. Multimedia Appendix 1 provides further details
on the utility values assigned to (post-)surgery health states.
We come back to the observed differences in the Discussion
section.
Treatment Effect
The treatment effect of the included studies was based on a wide
range of sources. An overview of the trials is provided in
Multimedia Appendix 1. Several authors conducted a network
meta-analysis for both the induction and maintenance phases
[17,21,22]. Other studies performed an indirect comparison.
For example, in the study of Assasi et al [18], the initial
remission and response rates for IFX were derived from the
12-week results of the 5 mg/kg arm that was reported by Targan
et al [37]. For ADA, the 4-week results of the 160 mg and 80
mg arm of the CLASSIC 1 study were used [38]. For the usual
care strategy, pooled rates from the placebo arms of these 2
trials were used to estimate remission and response rates. Bodger
et al [23] and Dretzke et al [20] selected the ACCENT I trial
[39] to model the IFX arm and the CHARM trial [29] for ADA.
This was also the case in the study by Kaplan et al [24].
However, in the latter study, the initial response rate to ADA
was retrieved from the GAIN study [40] that evaluated ADA
induction following IFX failure. In addition, the CADTH report
[19] referred to an indirect treatment comparison conducted by
the manufacturer to estimate the efficacy of treatments for
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inducing response or remission. Although most studies refer to
the CHARM trial [29] for information on ADA, Stawowczyk
et al [26] referred to the ULTRA 2 study [31] for estimates of
response and remission with ADA or SC.
Yu et al [28] relied on data from the CHARM [41] and
ACCENT I [42] trials to model results for the ADA and IFX
treatment arms. The authors remark that patient samples were
not equivalent at baseline. The CHARM trial included patients
with a maximum baseline CDAI score of 450 versus 400 for
ACCENT I [28]. Therefore, the sample of 234 ADA-treated
patients was weighted to have the same baseline median and
the same 25th and 75th percentile CDAI values, sex distribution,
and median age as those in the IFX arm of ACCENT I [28]. No
such adjustments were made in the other indirect comparisons.
Furthermore, strong assumptions are made. For example, Archer
et al [17] point out that in the MSD submissions, “patients who
have previously achieved a response can either maintain or lose
that response, but they cannot improve (i.e. they cannot
subsequently transit to the remission state). ...no additional
patients can achieve remission after induction and no patients
with remission can completely lose response during any given
model cycle.”
Incremental Cost-Effectiveness Ratios
In this overview, we focus on the results of treatment with ADA
and other biologicals (IFX, golimumab, and vedolizumab). For
a more detailed overview, we refer to sections 2.3.8 and 2.3.9
of Multimedia Appendix 1. Section 2.3.8 of Multimedia
Appendix 1 also includes overview tables presenting the results
of the identified economic evaluations.
In the study by Archer et al [17], when colectomy is an
alternative, colectomy is expected to dominate IFX, ADA,
golimumab, and conventional nonbiological treatments. When
elective colectomy is not an acceptable or preferred option, IFX
and golimumab are expected to be ruled out because of
dominance. The ICER of ADA versus conventional
nonbiological treatment is expected to be approximately £50,300
(approximately US $68,200) per QALY gained [17]. In the
AbbVie submission (marketing ADA–Humira), ADA had an
ICER of £34,590 (approximately US $46,900) per QALY
gained. In contrast, in the MSD submission (marketing IFX or
Remicade and golimumab or Simponi), ADA is expected to be
dominated by golimumab [17].
Assasi et al [18] calculated that usual care created the lowest
expected QALYs. However, the costs associated with ADA and
IFX could be perceived as high with ICERs of about CAD
193,000 (approximately US $152,000) per QALY and CAD
451,000 (approximately US $355,000) per QALY, respectively.
According to Bodger et al [23], IFX was always more expensive
and less effective than ADA, for which their model suggests
acceptable ICERs of less than £14,000 (approximately US
$19,000) per QALY [23].
CADTH evaluated the manufacturer’s pharmacoeconomic
evaluation. According to the manufacturer’s calculations,
golimumab has an ICER of about CAD 42,000 (approximately
US $33,000) per QALY and other biosimilars are (extendedly)
dominated. However, the Common Drug Review identified
several issues in the indirect treatment comparison and
assumptions that might bias the results in the favor of
golimumab [19].
Dretzke et al [20] did not mutually compare ADA and IFX. For
induction therapy, both biosimilars dominated SC in the
management of severe CD. For moderate CD, only ADA was
dominant relative to SC. Neither drug was considered
cost-effective as maintenance therapy with ICERs of about £5
million (approximately US $6.8 million) per QALY and £14
million (approximately US $19 million) per QALY for ADA
and IFX, respectively [20].
According to the manufacturer’s analysis reviewed by Essat et
al [21], vedolizumab dominates surgery, IFX, and golimumab.
Compared with ADA, the ICER of vedolizumab is estimated
at £6634 (US $8990) per QALY. In contrast, according to the
Evidence Review Group (ERG), surgery is likely to dominate
all medical treatments. If surgery is not an option, the review
group indicates that vedolizumab is expected to be dominated
by ADA [21].
Kaplan et al [24] estimated that IFX dose escalation yielded
0.03 extra QALYs compared with the ADA strategy. However,
in combination with an extra cost of more than $10,000, this
results in an ICER of more than $330,000 per QALY [24].
In comparison with nonbiological pharmacotherapy, Loftus et
al [25] calculated ADA has an ICER of about £16,000
(approximately US $21,700) per QALY and £34,000
(approximately US $46,000) per QALY in the treatment of
severe or moderate-to-severe CD, respectively [25].
In the study by Rafia et al [22], ADA provided 0.21 additional
QALYs in comparison with conventional nonbiological therapy
for an additional cost of £4000 (approximately US $5400),
resulting in an ICER of about £19,000 (approximately US
$25,700) per QALY. Vedolizumab was extendedly dominated.
IFX provides 0.0383 additional QALYs in comparison with
ADA for an additional cost of approximately £4400
(approximately US $6000), leading to an ICER of almost
£116,000 (approximately US $157,000) per QALY [22].
In addition, the study of Stawowczyk et al [26] indicated that
ADA is more effective and more costly than SC. One-year ADA
treatment results in an ICER of €71,000 (approximately US
$86,700) or €76,000 (approximately US $92,800) per QALY,
depending on the perspective [26].
Tang et al [27] compared several treatments after SC failed. No
significant differences in efficacy were calculated between the
4 biological treatments (IFX, ADA, certolizumab pegol, and
natalizumab). They produce similar QALYs with overlapping
95% CIs. On the basis of Monte Carlo simulations, IFX had the
highest probability of being the most cost-effective therapy
compared with the other biological treatment options [27].
In contrast with the previous study, Yu et al [28] calculated that
ADA delivers more QALYs and saves approximately $4900 in
comparison with IFX. On the basis of the probabilistic analysis,
ADA dominates IFX in approximately 94% of the simulations
and is the preferred biological treatment option [28].
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Almost all studies performed both probabilistic sensitivity
analysis and scenario analyses or one-way sensitivity analyses
to estimate the uncertainty surrounding estimates of incremental
costs, incremental effects, and ICERs. Only Kaplan et al [24]
did not perform a probabilistic sensitivity analysis.
Multimedia Appendix 1 gives an overview of the most
determining variables, as indicated by the authors of the original
economic evaluations. The most often mentioned variables are
the treatment effect [18,20,21,24,27], utilities [17,21,22,27],
and time horizon [18-23,25]. Some authors also highlight the
importance of the treatment duration [21,23,26], drug treatment
costs [24,27], health state costs [17,21], and patient weight [18].
Discussion
An overview of the economic literature allows us to identify
important issues related to (the calculation of) the
cost-effectiveness of ADA. A major strength is that this exercise
was performed before the trial was started. This way, we avoid
that important information to allow the performance of a
high-quality economic evaluation was not measured in the trial.
In the first part of this discussion, issues identified from the
review of the economic literature relevant to the REDUCE-RISK
trial are discussed. On the basis of these issues and expert
opinion, input is provided to ameliorate the protocol of the
REDUCE-RISK trial from a health economic point of view.
The added questionnaires are discussed in the second part of
this discussion.
Issues Identified in the Economic Literature Review
Related to the REDUCE-RISK Trial
Pediatric Population
All the identified economic evaluations performed an analysis
for an adult population. Two studies also included a secondary
analysis for the pediatric population [17,20]; however, efficacy
data still relied on trials that included only an adult population.
The analysis also did not include youngest children. Archer et
al [17] reported that patients’ starting age in their pediatric
population was 15 years. The lack of information related to the
treatment effect of biologicals in pediatric patients means that
the results of such secondary analyses should be interpreted
with caution. Archer et al [17] suggested RCTs assessing the
clinical effectiveness of biologicals in pediatric patients as a
research priority. This makes the conduct of the REDUCE-RISK
trial, which includes patients aged 6 to 17 years, very
worthwhile.
Severity of Disease
Almost all studies explicitly include a population with
moderate-to-severe CD or UC disease. Only two reports
differentiate results according to disease severity. Dretzke et al
[20], inclusive of the Abbott submission discussed in the same
report, distinguish between severe and moderate disease. Loftus
et al [25] performed calculations for severe CD and
moderate-to-severe CD. They did not perform a separate analysis
for the moderate CD patients. Such a distinction is important
in economic evaluations as applying the same relative treatment
effect to a higher baseline risk for a specific event results in a
larger absolute treatment effect. The severity of disease might
have a significant impact on an intervention’s ICER. Making
an explicit distinction in the REDUCE-RISK trial between
patients at low or high risk for aggressive disease course is
desirable from both clinical and economic points of view.
Adalimumab Versus Other Biological Treatment Options
In most of the identified economic evaluations, ADA has a
better cost-effectiveness than the other biologicals. In the study
by Archer et al [17], IFX and golimumab are expected to be
ruled out in the economic analysis because of dominance (less
effective and more expensive), whereas the ICER of ADA
versus conventional nonbiological treatment is expected to be
approximately £50,300 (approximately US $68,200) per QALY
gained [17]. In the study by Assasi et al [18], the ICER of ADA
versus usual care is relatively high (approximately CAD 193,000
[US $152,000] per QALY); however, this is even higher for
IFX versus ADA (CAD 451,000 [approximately US $355,000]
per QALY). In the study by Bodger et al [23], IFX is dominated
by ADA.
In the study by Dretzke et al [20], IFX and ADA are not
mutually compared. However, the findings of the economic
model were in favor of ADA: for induction, both ADA and IFX
were cost-effective (dominant relative to SC) in the management
of severe CD, and ADA was cost-effective for moderate CD
(dominant relative to SC) [20].
In the study by Essat et al [21], according to the ERG group,
vedolizumab is expected to be dominated by ADA if surgery
is not an option [21].
The results of the study by Rafia et al [22] indicate that,
assuming a cost-effectiveness threshold of £30,000
(approximately US $40,000) per QALY, ADA has the highest
probability of being the most cost-effective intervention (78%).
Similarly, in the study by Yu et al [28] based on the probabilistic
analysis, ADA dominates IFX in approximately 94% of the
simulations.
In the US study of Tang et al [27], IFX and ADA are about
equally effective and IFX is cheaper. Finally, Loftus et al [25]
and Stawowczyk et al [26] only compared ADA with
conventional nonbiological treatment.
On the basis of the aforementioned information, most of the
economic studies were in favor of ADA in comparison with
other biologicals. Only in the manufacturer’s submissions, the
conclusion is different. For example, in the MSD submission
[marketing IFX or Remicade and golimumab or Simponi), ADA
is expected to be dominated by golimumab [17]. However, the
manufacturer’s submission includes a discount for the drug. If
this discount is not taken into account, golimumab is ruled out
because of extended dominance. Similarly, in a Canadian study,
according to the manufacturer’s calculations, golimumab has
an ICER of approximately CAD 42,000 (approximately US
$33,000) per QALY and IFX and ADA are (extendedly)
dominated [19].
Most of the identified studies indicate that ADA has a better
cost-effectiveness than the other biologicals included in the
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analyses, and thus, from a health economic point of view, it
seems to be a justified biological intervention in future trials.
Nevertheless, in economic evaluations, it is important to work
on the efficiency frontier, that is, comparing treatments with
the next best non-(extendedly) dominated intervention. From a
health economic point of view, it is important to make an
incremental analysis and include SC in the analysis and not
immediately compare biologicals with each other. As mentioned
by Dretzke et al [20], this would only be relevant “where both
adalimumab and infliximab have been first justified as
maintenance therapies versus standard care (SC). Where one
or both maintenance therapies are not cost-effective versus SC,
this comparison provides no information to decision-makers.”
Therefore, from a health economic point of view, we considered
it justified to compare methotrexate with ADA in the high-risk
patient group of the REDUCE-RISK trial.
Treatment Effect
The input for the conventional nonbiological, ADA, and IFX
treatment is often based on the CLASSIC I [43], CHARM [29],
and ACCENT I [39,42] trials, respectively. However, comparing
outcomes from individual treatment arms of separate trials might
bias the results, and the direction of this bias is unknown.
Head-to-head RCTs are needed to allow an unbiased comparison
of biological therapy with SC. It is also necessary to set up
reliable health economic models to estimate the intervention’s
cost-effectiveness. The REDUCE-RISK trial is an example of
such a head-to-head RCT.
QoL
The EUnetHTA guideline for methods for health economic
evaluations recommends that results be presented in terms of
both a cost-effectiveness analysis and a cost-utility analysis
[44]. The primary outcome measures should, where appropriate,
be presented as natural units (including life years) and as
QALYs [44]. The health-related quality of life (HRQoL) aspects
of the QALY were captured in a HRQoL weight. On the basis
of the review of guidelines used by EUnetHTA partners, EQ-5D
is the most commonly recommended instrument for deriving
HRQoL weights, although other instruments are also mentioned
(eg, Health Utility Index, Short-Form 6-Dimension, or
15-dimensional) [44].
A major limitation is that none of the underlying trials measured
QoL with a generic utility instrument. As a result, the authors
of the economic evaluations have to make many assumptions
in their models. Previous reviewers also noticed strange
assumptions regarding utility values that are linked to health
states. For example, Essat et al [21] reported that the utility
value in postsurgical remission was lower than for moderate or
severe disease (0.60 vs 0.68), which appears to be inconsistent.
Bodger et al [23] transformed CDAI scores to utilities, based
on an algorithm developed by Buxton et al [35]. In this study,
the correlation between CDAI and EQ-5D is −0.62, and 29%
of the variability in EQ-5D scores is explained by CDAI [35].
However, Buxton et al [35] mention in their discussion that
“based on the variance explained, the relationships between the
CDAI and utilities in the simple models are weaker than those
for the IBDQ [Inflammatory Bowel Disease Questionnaire] and
suggest that the CDAI provides a poorer basis for estimating
utilities. Again its relatively poor performance as a predictor of
utility reflects its main role as clinical indicator of disease
activity, rather than of HRQoL.” In the absence of utility values
for surgery, Dretzke et al [20] assumed that this health state is
represented by the EQ-5D state 22222, which has a UK utility
weight of 0.516. Such assumptions are arbitrary and not very
reliable. As the model results are sensitive to such utility
assumptions, better evidence-based input is desirable. In the
REDUCE-RISK trial, this is taken into account by including
the EQ-5D questionnaire in the research protocol (see the second
part EQ-5D of this discussion).
Indirect Costs
Finally, the studies are performed from a health care payer’s
perspective, which excludes indirect nonhealth care related
costs, such as costs related to lost productivity. In contrast,
indirect costs would represent a substantial portion of the costs
of CD. A US study indicates that this accounts for 28% of the
total CD cost in the United States [45]. Only 2 studies [25,26]
included a scenario with the inclusion of these costs. In the
Polish study, based on an unpublished study, yearly indirect
costs for remitted patients counted to PLN 6524 (US $1767).
This was PLN 22,935 (US $6211) for patients with active
disease. Loftus et al [25] indicate that “including indirect costs
related to lost productivity due to hospitalization improved the
cost-effectiveness of adalimumab therapy. However, the
estimate of indirect costs was likely substantially underestimated
because only work missed during hospitalization was included.
Other indirect costs, such as decreased productivity at work and
labor force nonparticipation, were not included.” Assasi et al
[18] also reported that if a societal perspective was taken and
indirect costs were included in the model, the cost-effectiveness
of anti-TNFs compared with that of usual care likely would
have been lower. In addition, Yu et al [28] claim that reliable
data sources to include the impact on indirect costs are lacking.
Efforts should be taken to gather reliable information about the
impact of different treatments on indirect costs. In the next part
of this discussion, we discuss how measures for school
attendance and parents’productivity are included in the research
protocol of the REDUCE-RISK trial.
Added Elements in the REDUCE-RISK Trial Research
Protocol
As recommended by the EUnetHTA guidelines on HRQoL [46],
future studies should include a generic utility instrument in
complement to disease-specific questionnaires to adequately
capture the impact of a disease on daily life. Including a generic
utility instrument in further research is also suggested as a
research priority by the reviewers in the study by Archer et al
[17] and Dretzke et al [20] and the underlying NICE report [16].
The disease-specific IMPACT-3 HRQoL measure was already
included in the protocol. On the basis of the aforementioned
data, a generic utility instrument (EQ-5D) is added to the
research protocol. The ISPOR guidelines also recommend
“prioritization of high-cost resources as well as those that are
expected to differ between treatment arms, without distinction
as to whether they are related to disease or intervention [47].
The scope of resources considered should include direct medical
and nonmedical resources and indirect or productivity costs
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across patients and caregivers.” [4]. Similar to previous
economic evaluations, differences in treatment costs and costs
related to AEs will be taken into account. In addition, in the
REDUCE-RISK trial, children’s school attendance and parents’
productivity will also be measured.
EQ-5D
The economic literature review identified the lack of QoL data
that could be expressed as utilities and also indicated this as a
research priority. Following the EUnetHTA guidelines on
HRQoL [46], such information will be included in the
REDUCE-RISK trial through the inclusion of the generic EQ-5D
questionnaire.
In patients with CD and UC, a study by Stark et al [48] showed
that both the EQ-VAS (EuroQol-visual analog scale) and EQ
index scores correlate well with disease activity indices and
differ significantly between active disease and remission groups.
The authors concluded that the EQ-5D generates valid, reliable,
and responsive preference-based evaluations of health in CD
and UC. The EQ-VAS scores were more responsive than EQ-5D
index scores, and thus, small health differences that are
important from the patient's perspective may not be reflected
in the EQ index [48]. This is in line with the results from a
previous study from this research group that also concluded the
EQ-5D to be “reasonably valid, reliable and responsive in
patients with inflammatory bowel disease. It can be used to
generate preference-based valuations of health-related quality
of life in inflammatory bowel disease.” [49].
From a practical point of view, the time for completion is less
than 2 min for the EQ-5D [50]. From a financial point of view,
the EQ-5D could be used free of charge for this study.
Three EQ-5D questionnaires are included: the EQ-5D-Y (youth
version), EQ-5D-Y proxy1, and EQ-5D-5L.
1. The EQ-5D-Y was administered to measure the children’s
QoL. Following the user’s guidelines, the youth version is
used for all patients included in the REDUCE-RISK trial:
“A study only with children up to 18 years, in this case
EQ-5D-Y for older children would be recommended in
order to have only one EQ-5D version in the study. The
switch-over to the adult version could bring discontinuity
as the adult and child versions are two different
instruments.” [51].
2. In the youngest children (<8 years), it is not possible to
apply a self-completing questionnaire. We ask one of the
parents to fill in the proxy version. The proxy rates how he
or she rates the child’s health. “The use of proxies, such as
caregivers or family, should be avoided where possible.
However, the use of proxies for the measurement of HRQoL
is unavoidable in some cases, e.g. cognitively impaired
patients, small children.” [46]. By asking this for all
patients, we will be able to evaluate the agreement between
self- and proxy-reports of the EQ-5D-Y questionnaire.
3. The EQ-5D-5L was used to measure parents’ QoL. It is
important to find ways of incorporating relatives’ costs and
effects when these might be substantial and may influence
the ICERs [52]. Parents’ QoL of children with CD or UC
might be such an example. This has not been included in
any of the identified studies, and thus, the impact is unclear.
Davidson et al [52] stated that the most relevant outcome
measure to use for relatives’ effects would be their affected
utility. Therefore, we also included the measurement of
parents’ QoL through the use of the EQ-5D questionnaire.
There is a choice between the 3L and 5L versions. The
EQ-5D-5L version might be more sensitive to changes in
health status in comparison with the 3L version [53,54].
Schwenkglenks et al [55] expect that the 5L version will
gradually replace the 3L version, because of reduced ceiling
effects and more appropriate responsiveness. Goldsmith et
al [56] also referred to the increased ability to discriminate
health states, which may improve the prediction of EQ-5D
index values. Therefore, the EQ-5D-5L version was used.
The QoL measurements were made at baseline and all following
planned study visits (months 2, 4, 6, 9, and 12). More
information about the EQ-5D questionnaires, the included
language version, the available value sets, and a sample version
is available in section 3.1 of Multimedia Appendix 1.
School Attendance
A review of the economic literature indicates that indirect costs
might represent a substantial portion of costs related to CD and
UC but that the impact of different treatment options on such
costs is lacking. As the patient population in the REDUCE-RISK
trial is restricted to children and adolescents aged 6 to 17 years,
indirect costs do not immediately relate to the patient’s
productivity. Instead, we try to measure the impact on a patient’s
school attendance.
Three studies were identified measuring the impact of CD or
UC on school performance [57-59]. One study used a
semistructured questionnaire for both children and parents and
found that significant psychosocial and academic difficulties
are faced by children with chronic diseases such as IBD [57].
Children with CD and UC missed significantly more school
days than age-matched healthy controls [57]. Another study
[58] created an online survey that included a Student Adaptation
to College Questionnaire (SACQ). The results show that
“disease activity in students with CD was associated strongly
with their self-reported ability to keep up with academic work
(P<.0089) and confidence in their ability to meet future
academic challenges (P<.0015). Students with active IBD
reported feeling as if they were not academically successful
(P<.018), and students with ulcerative colitis reported irregular
class attendance (P<.043).” [58]. The third study obtained report
cards and school absence information from schools. Children
with IBD had poorer school functioning and significantly more
absences [59]. None of these studies used a structured
questionnaire that was validated for use in children with CD or
UC. The SACQ questionnaire is a 67-item, self-report
questionnaire that is for college students and is mainly used at
universities for routine freshman screening. This is considered
inappropriate for our research.
An additional nonsystematic Google search was performed to
identify other potentially relevant questionnaires. However,
these questionnaires are very general. For example, the School
Attendance Questionnaire mentions that these questionnaires
are generally designed by school authorities to find out the
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reasons for missing school. However, the questions posed clearly
indicate that this questionnaire of school attendance is not well
placed to apply in a population of sick children (eg, “Are your
parents aware of this attendance percentage?” or “Are you aware
that ...can lead to your suspension from school?”). Other
researchers proposed a novel method for measuring class
attendance by using location and Bluetooth data collected from
smartphone sensors [60]. This is not applicable for the youngest
children in our population because they usually do not have a
smartphone.
No well-suited questionnaire was thus identified that can be
used for the international REDUCE-RISK trial. Therefore, a de
novo school attendance questionnaire was set up. Limitations
of this questionnaire are that it is nonvalidated and that we
cannot rely on the experience of other researchers with this
questionnaire. Nevertheless, the choice was made to use this
new instrument because we preferred to take the initiative to
try to measure the impact with a nonvalidated instrument instead
of not trying to measure this important aspect. The school
attendance questionnaire consists of a version that is used at the
first visit and a version to be used at the follow-up visits.
The parents filled in the questionnaire. First, we asked them to
give a general picture of a typical school week to be able to
have a view on the number of days the child goes to school in
a typical week (exclusive home education) and the presence of
home schooling (or home education). The aim of the
questionnaire is to estimate the impact of IBD (CD and UC)
and its treatment on school attendance and home education. The
questions are related to the following: the presence and amount
of home education; whether home education is because of IBD;
the percentage of school days that children could not attend; in
the case of home education, the percentage of home schooling
days that children could not attend; and for both school days
and home education, the part of absence that is because of IBD
(in the opinion of the parents).
To assist participants with accurate recall, the ISPOR guidelines
[4] recommend economic investigators to consider using
memory aids such as diaries to record medical visits and events.
Investigators should inform participants that they will be asked
to report this information throughout the trial [61]. In line with
this recommendation, the last page of the questionnaire, entitled
Information for parents to take home to help in collecting
information for the next follow-up visit, contains an overview
of the questions.
Further details on the timing of the measurements and a sample
version of these questionnaires are available in section 3.2.1 of
Multimedia Appendix 1.
Parents’ Productivity
To improve the quality and uniformity of data generated from
trials, the ISPOR guidelines [4] recommend using validated
instruments when incorporating productivity costs [62-64]. The
Work Productivity and Activity Impairment (WPAI)
questionnaire [65] is a self-administered questionnaire assessing
the impact of a disease on a patient's ability to work and/or
perform nonwork activities. A version exists specifically for
CD (WPAI:CD), and a caregiver version (WPAI:CD-CG) exists
in which the effect of a child's specific health problem on the
parent's work productivity is measured. This WPAI:CD-CG
questionnaire is included in the REDUCE-RISK trial. The
included questions are related to the following: Q1: current
employment, Q2: hours missed because of problems associated
with the child’s CD, Q3: hours missed for other reasons, Q4:
hours actually worked, Q5: degree child’s CD affected
productivity while working, and Q6: degree child’s CD affected
regular activities. The questionnaire is available at no charge
in several languages. Details about the scores that will be
calculated from these questions and the timing of measurements
are available in section 3.2.2 of Multimedia Appendix 1.
Conclusions
This paper addresses an important and progressive issue:
including health economic considerations in the design of
clinical trials. At the end of the trial, when all information on
the intervention’s efficacy and safety has been gathered, the
important incremental variables will be combined in a trial-based
economic evaluation calculating the intervention’s incremental
costs, effects, and ICERs, both from a health care payer and
societal perspective. Guidelines for performing economic
evaluations will be followed. For example, parameter uncertainty
will be included by performing a probabilistic sensitivity
analysis. Following the ISPOR guidelines, reporting of the
methods and results of the economic evaluation will be
performed according to the CHEERS guidelines [11,12].
In conclusion, we are of the opinion that performing a systematic
literature review supports researchers in setting up a research
protocol. In our case, the results of the literature review helped
us to identify important variables for which evidence should be
gathered in the REDUCE-RISK trial to allow the performance
of a high-quality economic evaluation.
Conflicts of Interest
LR received a consultancy fee or a grant from Pfizer, Abbvie, Celltrion, ZonMw in the previous 3 years. NC’s institution received
speaker fees, advisory board fees, and research funding from Abbvie, Eli Lilly, Takeda, Shire, Pfizer, Jansenn, Allergan, 4D
Pharma. SK reports grants from Mead Johnson, Nestec Nutrition, BioGaia, personal fees from Nestle, Danone, Biocodex, Shire,
Abbvie, R-Biopharm, Vifor, Pharmacosmos, Celgene, ThermoFisher, Pfizer, Janssen, outside the submitted work. AL report to
have IP or received travel grants, speakers’ honoraria, research grants from Nestle, Janssen, AbbVie, Megapharm and Takeda.
DT received consultation fee, research grant, royalties, or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring,
Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS during the last 3 years. FR received consultation
fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Celgene, Nestlé Health Science, Nestlé Nutrition Institute
during the last 3 years.
JMIR Form Res 2021 | vol. 5 | iss. 1 | e13888 | p. 12http://formative.jmir.org/2021/1/e13888/
(page number not for citation purposes)




Paediatric inflammatory bowel diseases network for safety, efficacy, treatment and quality improvement of care
(PIBD-SETQUALITY): economic evaluation considerations.
[PDF File (Adobe PDF File), 1656 KB-Multimedia Appendix 1]
Multimedia Appendix 2
Included and excluded studies (and reasons for exclusion).
[DOCX File , 35 KB-Multimedia Appendix 2]
Multimedia Appendix 3
PRISMA-2009-Checklist (literature review economic part REDUCE-RISK trial).
[DOC File , 194 KB-Multimedia Appendix 3]
References
1. Harris RE, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, PIBD SETQuality consortiumPIBDnet. Protocol for a
multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or
adalimumab for maintaining remission in patients at low or high risk for aggressive disease course. BMJ Open 2020 Jul
1;10(7):e034892 [FREE Full text] [doi: 10.1136/bmjopen-2019-034892] [Medline: 32611737]
2. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes.
Oxford, UK: Oxford University Press; 1997.
3. EUnetHTA European Network for Health Technology Assessment. Methods for health economic evaluations - a guideline
based on current practices in Europe. EUnetHTA 2015.
4. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical
trials II-An ISPOR Good Research Practices Task Force report. Value Health 2015 Mar;18(2):161-172 [FREE Full text]
[doi: 10.1016/j.jval.2015.02.001] [Medline: 25773551]
5. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ 2010 Mar;19(3):350-364. [doi:
10.1002/hec.1486] [Medline: 19378354]
6. Lofland JH, Mallow P, Rizzo J. Cost-per-remission analysis of infliximab compared to adalimumab among adults with
moderate-to-severe ulcerative colitis. J Med Econ 2013;16(4):461-467. [doi: 10.3111/13696998.2013.775134] [Medline:
23445401]
7. Toor K, Druyts E, Jansen JP, Thorlund K. Cost per remission and cost per response with infliximab, adalimumab, and
golimumab for the treatment of moderately-to-severely active ulcerative colitis. J Med Econ 2015 Jun;18(6):437-446. [doi:
10.3111/13696998.2015.1012513] [Medline: 25629655]
8. Liu Y, Wu EQ, Bensimon AG, Fan CS, Bao Y, Ganguli A, et al. Cost per responder associated with biologic therapies for
Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012 Jul;29(7):620-634. [doi: 10.1007/s12325-012-0035-7]
[Medline: 22843208]
9. Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological
therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol 2016;3(1):e000093 [FREE Full text] [doi:
10.1136/bmjgast-2016-000093] [Medline: 27195130]
10. Saro C, Ceballos D, Muñoz F, De la Coba C, Aguilar MD, Lázaro P, et al. Resources utilization and costs the year before
and after starting treatment with adalimumab in Crohn s disease patients. Inflammatory Bowel Diseases
2015;21(7):1631-1640. [doi: 10.1097/mib.0000000000000413]
11. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, CHEERS Task Force. Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med 2013 Mar 25;11:80 [FREE Full text] [doi:
10.1186/1741-7015-11-80] [Medline: 23531108]
12. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, ISPOR Health Economic Evaluation Publication
Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards
(CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good
Reporting Practices Task Force. Value Health 2013;16(2):231-250 [FREE Full text] [doi: 10.1016/j.jval.2013.02.002]
[Medline: 23538175]
13. Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, et al. A model-based economic evaluation of biologic
and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure
of conventional therapy. Pharmacoeconomics 2016 Oct;34(10):1023-1038. [doi: 10.1007/s40273-016-0409-9] [Medline:
27125898]
14. Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, et al. Canadian cost-utility analysis of initiation and
maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. J Crohns Colitis 2012 Feb;6(1):77-85. [doi:
10.1016/j.crohns.2011.07.007] [Medline: 22261531]
JMIR Form Res 2021 | vol. 5 | iss. 1 | e13888 | p. 13http://formative.jmir.org/2021/1/e13888/
(page number not for citation purposes)
Neyt et alJMIR FORMATIVE RESEARCH
XSL•FO
RenderX
15. Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, et al. Vedolizumab for the treatment of adults with
moderate-to-severe active ulcerative colitis: an evidence review group perspective of a nice single technology appraisal.
Pharmacoeconomics 2016 Mar;34(3):245-257. [doi: 10.1007/s40273-015-0334-3] [Medline: 26477040]
16. National Institute for Health and Care Excellence (NICE). Infliximab and adalimumab for the treatment of Crohn's disease's
(TA187). Technology appraisal guidance 2010. [doi: 10.1007/978-1-349-94186-5_836]
17. Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, et al. Infliximab, adalimumab and golimumab
for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of
TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016
May;20(39):1-326 [FREE Full text] [doi: 10.3310/hta20390] [Medline: 27220829]
18. Assasi N, Blackhouse G, Xie F, Gaebel K, Marshall J, Irvine E, et al. Anti-TNF-a drugs for refractory inflammatory bowel
disease: clinical- and cost-effectiveness analyses. In: Technology report number 120. Ottawa: Canadian Agency for Drugs
and Technologies in Health (CADTH); 2009:203.
19. Canadian Agency for Drugs and Technologies in Health (CADTH). golimumab (Simponi). Common Drug Review
Pharmacoeconomic Review Report 2014:1-29.
20. Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, et al. A systematic review and economic evaluation of the
use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol
Assess 2011 Feb;15(6):1-244 [FREE Full text] [doi: 10.3310/hta15060] [Medline: 21291629]
21. Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, et al. Vedolizumab for the treatment of adults with moderately
to severely active ulcerative colitis. In: A Single Technology Appraisal. Sheffield: School of Health and Related Research
(ScHARR); 2014.
22. Rafia R, Scope A, Harnan S, Stevens J, Stevenson M, Sutton A, et al. Vedolizumab for the treatment of adults with moderately
to severely active Crohn's disease. In: A Single Technology Appraisal. Sheffield: School of Health and Related Research
(ScHARR); 2014.
23. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses
incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009 Aug;30(3):265-274 [FREE Full text]
[doi: 10.1111/j.1365-2036.2009.04033.x] [Medline: 19438428]
24. Kaplan G, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in
Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007 Dec;26(11-12):1509-1520 [FREE Full text]
[doi: 10.1111/j.1365-2036.2007.03548.x] [Medline: 17931345]
25. Loftus EV, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of
remission in patients with Crohn s disease. Eur J Gastroenterol Hepatology 2009;21(11):1302-1309. [doi:
10.1097/meg.0b013e32832a8d71]
26. Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard
care alone for ulcerative colitis in Poland. Eur J Clin Pharmacol 2016 Nov;72(11):1319-1325 [FREE Full text] [doi:
10.1007/s00228-016-2103-4] [Medline: 27497991]
27. Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Pharmacotherapy 2012 Jun;32(6):515-526. [doi: 10.1002/j.1875-9114.2011.01053.x] [Medline: 22528603]
28. Yu AP, Johnson S, Wang S, Atanasov P, Tang J, Wu E, et al. Cost utility of adalimumab versus infliximab maintenance
therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 2009;27(7):609-621.
[doi: 10.2165/11312710-000000000-00000] [Medline: 19663531]
29. Colombel J, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical
response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 Jan;132(1):52-65. [doi:
10.1053/j.gastro.2006.11.041] [Medline: 17241859]
30. Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, et al. Managing the long term care of inflammatory
bowel disease patients: the cost to European health care providers. J Crohns Colitis 2011 Aug;5(4):301-316. [doi:
10.1016/j.crohns.2011.02.005] [Medline: 21683300]
31. Sandborn WJ, van Assche G, Reinisch W, Colombel J, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains
clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012 Feb;142(2):257-65.e1. [doi:
10.1053/j.gastro.2011.10.032] [Medline: 22062358]
32. Woehl A, Hawthorne A, McEwan P. The relation between disease activity, quality of life and health utility in patients with
ulcerative colitis. Gut 2008;57(Suppl. 1):A153.
33. Swinburn P, Elwick H, Bean K, Curry A, Patel S, Bodger K, et al. The Impact of Surgery on Health Related Quality of
Life in Ulcerative Colitis. Digestive Disorders Federation Meeting. Liverpool: Gut Conference; 2012.
34. Gregor JC, McDonald JW, Klar N, Wall R, Atkinson K, Lamba B, et al. An evaluation of utility measurement in crohn s
disease. Inflammatory Bowel Diseases 1997;3(4):265-276. [doi: 10.1097/00054725-199712000-00004]
35. Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ. Mapping from disease-specific measures to
utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity
Index in Crohn's disease and measures of utility. Value Health 2007;10(3):214-220 [FREE Full text] [doi:
10.1111/j.1524-4733.2007.00171.x] [Medline: 17532814]
JMIR Form Res 2021 | vol. 5 | iss. 1 | e13888 | p. 14http://formative.jmir.org/2021/1/e13888/
(page number not for citation purposes)
Neyt et alJMIR FORMATIVE RESEARCH
XSL•FO
RenderX
36. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance
therapy for crohn's disease. N Engl J Med 2005 Nov 3;353(18):1912-1925. [doi: 10.1056/nejmoa043335]
37. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric
monoclonal antibody ca2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997 Oct 9;337(15):1029-1036.
[doi: 10.1056/nejm199710093371502]
38. Sandborn W, Lukas M, Rutgeerts P, Pollack P, Kent J. Fully human anti-TNF adalimumab maintains remission for one
year in patients with active Crohn's disease: a randomised, controlled cohort [abstract]. Gut 2006;55(Suppl 2):A27.
39. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's
disease: the ACCENT I randomised trial. Lancet 2002 May;359(9317):1541-1549. [doi: 10.1016/s0140-6736(02)08512-4]
40. Sandborn WJ, Rutgeerts P, Enns RA, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab rapidly induces clinical
remission and response in patients with moderate to severe crohn s disease who had secondary failure to infliximab therapy.
Am J Gastroenterol 2006;101:S448. [doi: 10.14309/00000434-200609001-01147]
41. Colombel J, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, et al. Comparison of two adalimumab treatment
schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009
May;104(5):1170-1179. [doi: 10.1038/ajg.2009.59] [Medline: 19352339]
42. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic
treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 Feb;126(2):402-413. [doi:
10.1053/j.gastro.2003.11.014] [Medline: 14762776]
43. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor
monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 Feb;130(2):323-33;
quiz 591. [doi: 10.1053/j.gastro.2005.11.030] [Medline: 16472588]
44. EUnetHTA - European Network for Health Technology Assessment. Methods for health economic evaluations - A guideline
based on current practices in Europe. EUnetHTA 2015.
45. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other Western
countries: a systematic review. Curr Med Res Opin 2008 Feb;24(2):319-328. [doi: 10.1185/030079908x260790] [Medline:
18067689]
46. EUnetHTA - European Network for Health Technology Assessment. Endpoints used for relative effectiveness assessment:
health-related quality of life and utility measures. EUnetHTA 2015.
47. Glick H, Doshi J, Sonnad S, Polsky D. Economic Evaluation in Clinical Trials. New York, USA: Oxford University Press;
2015.
48. Stark RG, Reitmeir P, Leidl R, König HH. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel
disease in Germany. Inflamm Bowel Dis 2010 Jan;16(1):42-51. [doi: 10.1002/ibd.20989] [Medline: 19475674]
49. König HH, Ulshöfer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, et al. Validation of the EuroQol questionnaire
in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002 Nov;14(11):1205-1215. [doi:
10.1097/00042737-200211000-00008] [Medline: 12439115]
50. Shearer D, Morshed S. Common generic measures of health related quality of life in injured patients. Injury 2011
Mar;42(3):241-247. [doi: 10.1016/j.injury.2010.11.044] [Medline: 21163477]
51. van Reenen M, Janssen B, Oppe M, Kreimeier S, Greiner W. EQ-5D-Y User Guide: Basic information on how to use the
EQ-5D-Y instrument (Version 1.0). EuroQoL 2014.
52. Davidson T, Levin L. Is the societal approach wide enough to include relatives? Appl Health Econ Health Policy 2012 Aug
6;8(1):25-35. [doi: 10.1007/bf03256163]
53. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L
compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res 2013 Sep;22(7):1717-1727
[FREE Full text] [doi: 10.1007/s11136-012-0322-4] [Medline: 23184421]
54. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new
five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011 Dec;20(10):1727-1736 [FREE Full text] [doi:
10.1007/s11136-011-9903-x] [Medline: 21479777]
55. Schwenkglenks M, Matter-Walstra K. Is the EQ-5D suitable for use in oncology? An overview of the literature and recent
developments. Expert Rev Pharmacoecon Outcomes Res 2016;16(2):207-219. [doi: 10.1586/14737167.2016.1146594]
[Medline: 26808097]
56. Goldsmith KA, Dyer MT, Buxton MJ, Sharples LD. Mapping of the EQ-5D index from clinical outcome measures and
demographic variables in patients with coronary heart disease. Health Qual Life Outcomes 2010 Jun 4;8:54 [FREE Full
text] [doi: 10.1186/1477-7525-8-54] [Medline: 20525323]
57. Assa A, Ish-Tov A, Rinawi F, Shamir R. School attendance in children with functional abdominal pain and inflammatory
bowel diseases. J Pediatric Gastroenterol Nutr 2015;61(5):553-557. [doi: 10.1097/mpg.0000000000000850]
58. Almadani SB, Adler J, Browning J, Green EH, Helvie K, Rizk RS, et al. Effects of inflammatory bowel disease on students'
adjustment to college. Clin Gastroenterol Hepatol 2014 Dec;12(12):2055-62.e1. [doi: 10.1016/j.cgh.2014.03.032] [Medline:
24726907]
JMIR Form Res 2021 | vol. 5 | iss. 1 | e13888 | p. 15http://formative.jmir.org/2021/1/e13888/
(page number not for citation purposes)
Neyt et alJMIR FORMATIVE RESEARCH
XSL•FO
RenderX
59. Mackner LM, Bickmeier RM, Crandall WV. Academic achievement, attendance, and school-related quality of life in
pediatric inflammatory bowel disease. J Develop Behav Pediatr 2012;33(2):1-111. [doi: 10.1097/dbp.0b013e318240cf68]
60. Kassarnig V, Bjerre-Nielsen A, Mones E, Lehmann S, Lassen DD. Class attendance, peer similarity, and academic
performance in a large field study. PLoS One 2017;12(11):e0187078 [FREE Full text] [doi: 10.1371/journal.pone.0187078]
[Medline: 29117190]
61. Goossens ME, Mölken MP, Vlaeyen JW, van der Linden SM. The cost diary. J Clin Epidemiol 2000 Jul;53(7):688-695.
[doi: 10.1016/s0895-4356(99)00177-8]
62. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment
instrument. Pharmacoeconomics 1993 Nov;4(5):353-365. [doi: 10.2165/00019053-199304050-00006] [Medline: 10146874]
63. Lerner D, Amick 3rd B, Rogers W, Malspeis S, Bungay K, Cynn D. The work limitations questionnaire. Med Care
2001;39(1):72-85. [doi: 10.1037/t66378-000]
64. Prasad M, Wahlqvist P, Shikiar R, Shih YT. A review of self-report instruments measuring health-related work productivity:
a patient-reported outcomes perspective. Pharmacoeconomics 2004;22(4):225-244. [doi:
10.2165/00019053-200422040-00002] [Medline: 14974873]







CADTH: Canadian Agency for Drugs and Technologies in Health
CD: Crohn disease
CHEERS: Consolidated Health Economic Evaluation Reporting Standards
CRD: Centre for Reviews and Dissemination
EEN: exclusive enteral nutrition
EQ-VAS: EuroQol-visual analog scale
ERG: Evidence Review Group
HTA: health technology assessment
IBD: inflammatory bowel disease
ICER: incremental cost-effectiveness ratio
IFX: infliximab
ISPOR: International Society for Pharmacoeconomics and Outcomes Research
MTX: methotrexate
NICE: National Institute for Health and Care Excellence
QALY: quality-adjusted life years
QoL: quality of life
SC: standard care
UC: ulcerative colitis
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